A multicenter cohort describes Y96D as a KRAS G12C inhibitor resistance mechanism with direct therapeutic implications.
Tumor
1 article
A multicenter cohort describes Y96D as a KRAS G12C inhibitor resistance mechanism with direct therapeutic implications.